The Dermatology Digest

MARCH 10, 2025

Th e Phase 3b, randomized, double-blind, placebo-controlled clinical trial included 99 patients with moderate-to-severe plaque psoriasis. ” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed. .

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

MARCH 8, 2025

The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% All you need is chronic itch for six weeks or longer, nodules, pustules, excoriation, and scratching; You dont need a biopsy as that can confuse the clinical picture.

Safety 36

Safety Clinic Therapy Dermatology 36

Dermatology Times

APRIL 19, 2024

Researchers examined local skin reactions of a topical gel inhibiting cytosolic phospholipase A2 both in-clinic and remotely.

Technology 83

Technology Safety Clinic 83

Dermatology Times

SEPTEMBER 24, 2024

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

Safety 73

Safety Clinic 73

Dermatology Times

AUGUST 23, 2023

While botulinum toxin has emerged as a treatment course for rosacea in recent years, researchers are calling for more comprehensive and detailed long-term research to assess its effectiveness.

Rosacea 69

Rosacea Safety Clinic Treatments 69

AAAMS

DECEMBER 19, 2024

This foundational knowledge is critical for practitioners who wish to perform aesthetic procedures with precision, confidence, and a commitment to patient safety. Our facial aesthetics program provides a detailed understanding of facial anatomy, physiognomy, and essential techniques, such as Botox and dermal filler injections.

Medical 52

Medical Networking Ethics Surgery 52

Dermatology Times

MAY 30, 2024

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Sustainability 73

Sustainability Safety Clinic 73

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported. Robert Bard, VP of Regulatory Affairs at NovelMed Therapeutics. The post U.S.

Safety 36

Safety Therapy Clinic Dermatology 36

The Dermatology Digest

JANUARY 8, 2025

topical ET-02 may be more effective than existing treatments for androgenic alopecia, according to results of a first-in-man clinical trial. In a double-blind, placebo-controlled, dose-ranging clinical study of 24 subjects at three U.S. In a double-blind, placebo-controlled, dose-ranging clinical study of 24 subjects at three U.S.

Safety 36

Safety Clinic Pharmaceutical Treatments 36

The Dermatology Digest

JANUARY 28, 2025

AK006 disappointed in a Phase 1 study of chronic spontaneous urticaria (CSU), and the Company will discontinue further clinical development of AK006. The primary endpoint of the proof-of-concept cohort was safety and tolerability with therapeutic activity explored using the Urticaria Activity Score (UAS)-7 at 14 weeks. Allakos Inc.s

Safety 36

Safety Clinic Dermatology 36

Dermatology Times

MARCH 10, 2024

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

Safety 78

Safety Clinic 78

New Age Spa Institute

DECEMBER 18, 2024

In this blog, well build upon our discussion of licensure versus certification and explore the different classifications of certifications in esthetics and cosmetology, including Clinical Aesthetics and Master Clinical Aesthetics. Clinical Aesthetics Certification Who is this for? What Are Certifications? Want more info?

Medical 52

Medical Esthetics Legal Continuous Education 52

Dermatology Times

OCTOBER 12, 2023

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Safety 78

Safety Clinic 78

Kim Gallo Esthetics

FEBRUARY 27, 2024

From futuristic at-home devices to clinics equipped with state-of-the-art machinery, technology has placed the tools for radiant skin in the hands of the many. The accessibility of tools and treatments prompts questions about their efficacy and safety, reminding us to trust professionals for guidance and comprehensive understanding.

Skincare 294

Skincare Esthetician Skincare Routine Chemical Peels 294

Atelier Esthetique Institute of Esthetics

DECEMBER 5, 2023

Accrediting committees ensure that the quality and safety of your school is approved and noted by outside bodies. Atelier Esthetique has a clinic where our students can work for the general public. Thankfully, Atelier Esthetique Institute can help with our robust curriculum.

Esthetician 148

Esthetician Esthetics Education Training 148

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients.

Treatments 36

Treatments Office Therapy Clinic 36

Dermatology Times

OCTOBER 24, 2024

Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.

Safety 53

Safety Dermatitis Clinic 53

Alison Bladh

JANUARY 16, 2025

Clinical studies indicate that saw palmetto can be an effective option for managing urinary symptoms during perimenopause and menopause, improving quality of life for many women. Urinary Tract Support As women age, they often experience urinary symptoms such as frequent urination, urgency, and discomfort.

Extractions 98

Extractions Management Consultation Consultations 98

The Dermatology Digest

MARCH 9, 2025

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

Dermatology Times

APRIL 5, 2024

Researchers reviewed the efficacy and safety of omalizumab in patients with severe CSU in a routine clinical practice setting.

Safety 74

Safety Clinic 74

Dermatology Times

JUNE 10, 2024

Phase 3 clinical results showed that the safety and tolerability profiles were consistent with those observed in the original pivotal trials.

Safety 74

Safety Clinic 74

Dermatology Times

JUNE 2, 2024

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Safety 73

Safety Clinic 73

Kim Gallo Esthetics

DECEMBER 23, 2022

At Kim Gallo Esthetics, your comfort and safety is our top priority. It's hand-made here in the USA, FDA-cleared, and has been clinically proven to be effective. Microcurrent facials are considered to be very safe and can be used on all skin types.

Facials 195

Facials Esthetics Skin Types Collagen 195

The Dermatology Digest

MARCH 10, 2025

The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase (JAK) inhibitor medication. At week 24, 22.7%

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

NOVEMBER 30, 2024

LP-310, developed by Lipella Pharmaceuticals for the treatment of oral lichen planus (OLP), is currently in Phase 2 clinical trials. Lipella has received an Investigational New Drug (IND) approval for a Phase 2a multicenter dose-escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

MARCH 3, 2025

a clinic) or at home. We are excited to be able to provide DEB patients with the first treatment that corrects the genetic defect and makes a true difference in their lives, says Cristina Has, MD, Professor and Head of the Genodermatoses Clinic in the Department of Dermatology at the University of Freiburg in Germany, in a news release.

Therapy 36

Therapy Clinic Hospital Dermatology 36

Dermatology Times

OCTOBER 2, 2023

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Safety 78

Safety Clinic 78

AAAMS

DECEMBER 19, 2024

For healthcare professionals seeking a fresh challenge , aesthetic medicine offers a perfect blend of clinical expertise, artistic precision, and patient care. Understanding patient safety protocols and treatment planning. Personal Fulfillment: Helping patients feel more confident in their appearance can be incredibly rewarding.

Social Media 52

Social Media Work-Life Balance Training Microneedling 52

The Dermatology Digest

DECEMBER 9, 2024

This FDA clearance was supported by AiVivas submission of safety data on non-facial skin tolerability and efficacy, and systemic exposure from 67 subjects treated with AIV001 in basal cell carcinoma and in scar management. To date, AiViva has completed three clinical studies using intradermal injection of AIV001.

Injections 36

Injections Facials Scarring Sensitive Skin 36

Dermatology Times

JANUARY 4, 2024

The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.

Safety 78

Safety Clinic 78

Dermatology Times

JANUARY 27, 2025

A panelist discusses how laser treatments demonstrate a strong safety profile and proven efficacy for patients with acne, with clinical studies showing significant reduction in both inflammatory and noninflammatory lesions.

Safety 36

Safety Treatments Clinic 36

Dermatology Times

JANUARY 2, 2025

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36

Safety Dermatitis Management Clinic 36

Alison Bladh

JANUARY 1, 2025

Dermatology Clinics. Microblading: Safety and Efficacy in Eyebrow Enhancement. Clinical and Aesthetic Dermatology. Journal of Cosmetic Dermatology. Shapiro, J., & Maddin, S. Hair Restoration Techniques and Outcomes. H., & Harcourt, D.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Training Clinic 78

Online Laser Training

OCTOBER 11, 2019

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Hospital 78

Hospital Safety Training Clinic 78

West Lake Dermatology

MARCH 10, 2025

Preparing for Surgery Arrival at the Clinic Patients typically arrive at the clinic early in the morning, as Mohs surgery often takes several hours depending on how many stages are required. This initial step is essential for ensuring both patient safety and the precision of the procedure. How Long Does the Procedure Take?

Surgery 36

Surgery Scarring Clinic Injections 36

The Dermatology Digest

FEBRUARY 6, 2025

SPECTREM is an ongoing Phase 3b, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab in participants with low BSA (215%), moderate (Investigators Global Assessment [IGA]=3) plaque psoriasis involving 1 special sites (scalp, face, intertriginous, or genital).

Safety 36

Safety Dermatology Clinic 36